Top Stories
Hibsago (bepirovirsen) achieved a functional cure rate of 19% in the Phase III B-Well 1 and 2 studies.
Capricor is now seeking an approval for deramiocel to improve upper-limb function in patients with Duchenne muscular dystrophy (DMD) after an earlier application for DMD-associated cardiomyopathy ran into roadblocks.
Five patients treated with RGX-121 showed asymptomatic spinal abnormalities in expanded MRI monitoring, and the company now says it has no plans to file in the near term.
Keller, the current head of Daiichi's oncology business, will lead the company's newly created globally integrated commercialisation unit.
The Korean biotech said its asset, HM17321, brings a differentiated non-incretin mechanism to Roche's growing obesity pipeline.
Conference News
As Biogen and Eisai's Leqembi (lecanemab) has struggled to gain uptake in Alzheimer's disease, Biogen has pointed to the potential for blood-based diagnostics to help expand the therapy's market reach. Eli Lilly, whose Kisunla (donanemab) came second to the landscape, took a more proactive approach
LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimm...
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced ...
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –– Supplemental BLA will be supported by results from three Phase 3...
-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company foc...
